1. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer
- Author
-
Emily S. Chambers, Alwin Schuller, Stephen Wang, Dalia Ercan, Mika Lin, Pınar Özden Eser, Raymond M. Paranal, Nicolas Floc'h, Sangeetha Palakurthi, Alison D. Santucci, Jeffrey J. Okoro, Geoffrey R. Oxnard, Man Xu, Kenneth H. Ngo, Jeanelle Tsai, Ciric To, Lynette M. Sholl, George Q. Daley, Michael Dills, Pavlos Missios, Kesi Michael, Paul D. Smith, Yoonji Eum, Magda Bahcall, Yanan Kuang, David A. Barbie, Masahiko Yanagita, Jennifer C. Heng, Rana Anjum, Prafulla C. Gokhale, Elena Ivanova, Jieun Son, Kshiti Dholakia, Heidi M. Haikala, Darren Cross, Jihyun Choi, Michael J. Poitras, Pasi A. Jänne, Timothy Lopez, Cloud P. Paweletz, and Atsuko Ogino
- Subjects
biology ,business.industry ,Extramural ,Mutant ,General Medicine ,Drug resistance ,medicine.disease ,Cancer research ,biology.protein ,Medicine ,Single agent ,Clinical efficacy ,Non small cell ,Epidermal growth factor receptor ,business ,Lung cancer - Abstract
A subset of drug-resistant EGFR -mutant MET -amplified lung cancer switches oncogenic dependence to MET and is treatable with MET inhibitor monotherapy.
- Published
- 2021
- Full Text
- View/download PDF